S-1/A: Virpax Pharmaceuticals Seeks Up to $4.5 Million in Public Offering to Fund Clinical Trials and Operations

Virpax Pharmaceuticals is offering up to 6,883,260 shares of common stock and pre-funded warrants in a best efforts offering to raise capital for clinical trials, working capital, and general corporate purposes.

Summary

• Virpax Pharmaceuticals is conducting a best efforts public offering of up to 6,883,260 shares of common stock and pre-funded warrants.
• The assumed public offering price is $0.7264 per share, based on the last reported sale price on Nasdaq on November 6, 2024.
• The company intends to use the net proceeds, estimated at $4.5 million if all shares are sold, to fund clinical trials for Probudur, working capital, and general corporate purposes.
• Up to $2.0 million may be allocated for marketing and advertising services.
• The offering will terminate on November 25, 2024, unless fully subscribed or terminated earlier.
• Spartan Capital Securities, LLC is acting as the exclusive placement agent.
• The company has implemented cost-cutting measures, including salary reductions and the elimination of D&O insurance.
• Virpax is facing challenges to maintain its Nasdaq listing due to stockholders' equity and minimum bid price requirements.
• Recent management changes include the appointment of Jatinder Dhaliwal as CEO and the resignation of Gerald Bruce and Vinay Shah.
• The company recently settled litigation with Sorrento and Scilex for $6 million plus royalties.
• Virpax is an emerging growth company and a smaller reporting company, allowing for reduced reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential for funding clinical trials and the settlement of litigation, the company's financial challenges, cost-cutting measures, and Nasdaq listing concerns weigh heavily on the overall outlook.

Positives

• The public offering aims to provide necessary capital to advance the clinical development of Probudur.
• The company has exclusive global rights to proprietary patented technologies.
• Virpax has implemented cost-cutting measures to conserve capital.
• The company has settled litigation with Sorrento and Scilex, removing a significant legal overhang.
• Positive results were announced for a Swine Model pilot study for Probudur.
• The company has the option to extend the Outside Date by up to thirty (30) days at the Company’s sole discretion, subject to approval by the Board, if the Company requires additional time to complete the re-audit of its financial statements for the fiscal years ended December 31, 2022, and 2023.

Negatives

• The company has a limited operating history and has consumed substantial amounts of cash since inception.
• Virpax has a stockholders deficit of $2,794,498 as of June 30, 2024.
• The company's cash position as of November 7, 2024, was approximately $0.1 million.
• The company is facing challenges to maintain its Nasdaq listing due to stockholders' equity and minimum bid price requirements.
• The company has implemented cost-cutting measures, including a 50% reduction in salaries and the elimination of D&O insurance, which may negatively affect employee morale and retention.
• The company recently settled litigation with Sorrento and Scilex for $6 million plus royalties of 6% of annual net sales of products developed from drug candidates Epoladerm, Probudur and Envelta.
• The company has eliminated its directors and officers insurance, which may affect retention, expose our directors and officers to personal liability, and impact our financial condition.

Risks

• The company requires substantial additional capital to fund its operations, and if it fails to obtain necessary financing, it will not be able to complete the development and commercialization of its drugs.
• The company may face challenges in retaining key personnel and maintaining business continuity as a result of recent cost-cutting measures, including salary reductions, which may also affect product development and timelines.
• The company's failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of its Common Stock.
• The company's management has broad discretion in using the net proceeds from this offering.
• The company's investors will experience immediate and substantial dilution in the net tangible book value of their shares.
• The company's offering may cause the trading price of its Common Stock to decrease.
• The company will not declare cash dividends on its Common Stock in the foreseeable future, so stockholders must rely on appreciation of the value of its Common Stock for any return on their investment.
• There is no public market for the Pre-Funded Warrants being offered in this offering.
• The company's purchasers who purchase its Securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.

Future Outlook

The company intends to use the net proceeds from this offering to fund its ongoing development activities for commencing clinical trial for Probudur, as well as for working capital and other general corporate purposes. In addition, the company may use up to $2.0 million for marketing and advertising services to communicate information about the Company to the financial community including, but not limited to, creating company profiles, media distribution and building a digital community with respect to the Company.

Industry Context

Virpax Pharmaceuticals operates in the competitive pharmaceutical industry, focusing on developing novel drug delivery systems for pain management and CNS disorders. The company's strategy aligns with the broader industry trend of seeking non-opioid and non-addictive pain management solutions.

Comparison to Industry Standards

• It is difficult to compare Virpax to industry standards due to its preclinical stage and limited operating history.
• Many comparable companies are further along in the clinical trial process.
• Virpax's financial situation is weaker than many of its peers, as evidenced by its stockholders' deficit and need for additional capital.
• The company's cost-cutting measures, while necessary, may put it at a disadvantage compared to better-funded competitors.

Management Changes

Legal Proceedings

• The company recently settled litigation with Sorrento and Scilex for $6 million plus royalties of 6% of annual net sales of products developed from drug candidates Epoladerm, Probudur and Envelta.

Stakeholder Impact

• Shareholders will experience dilution as a result of the public offering.
• Employees may be affected by cost-cutting measures, including salary reductions.
• The company's ability to develop and commercialize its product candidates will impact patients and the healthcare industry.
• The company's financial stability will affect its relationships with suppliers and creditors.

Next Steps

• The company intends to use the net proceeds from this offering to fund its ongoing development activities for commencing clinical trial for Probudur, as well as for working capital and other general corporate purposes.
• The company may use up to $2.0 million for marketing and advertising services to communicate information about the Company to the financial community including, but not limited to, creating company profiles, media distribution and building a digital community with respect to the Company.
• The company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Rule, including initiating a reverse stock split.

Key Dates

Keywords

public offering, pre-funded warrants, clinical trials, pharmaceutical, Virpax, capital raise, Probudur, Nasdaq, VRPX, financing